Adult vaccines market seen topping $62.7 billion by 2030

The adult vaccines market is projected to reach $62.74 billion by 2030, growing at a 9.5% CAGR, as governments and providers expand preventive immunization for older populations. North America is set to lead the market, while Pfizer remains the biggest player with a 30% share in 2025.

Why it matters: - Adult vaccination is becoming a bigger part of preventive care as infectious diseases, aging populations and public health programs push demand higher. - The market’s growth signals more spending on routine adult immunization, travel vaccines, workplace vaccination programs and next-generation formulations. - The category is becoming more important within both the broader vaccines market and the pharmaceuticals sector.

What happened: - The Business Research Company said the adult vaccines market is projected to grow at a 9.5% CAGR and reach $62.74 billion by 2030. - The report estimates adult vaccines will represent about 28% of the global vaccines market by 2030. - The same forecast says adult vaccines will make up close to 3% of the global pharmaceuticals market in 2030. - The report is titled The Adult Vaccines Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report includes a free sample request and a full report page.

The details: - North America is projected to be the largest regional market in 2030 at $25 billion. - North American adult vaccine sales are forecast to rise from $16 billion in 2025 to $25 billion in 2030, a 9% CAGR. - The USA is expected to be the largest single-country market in 2030 at $23 billion. - U.S. market value is forecast to increase from $16 billion in 2025 to $23 billion in 2030, also at a 9% CAGR. - The report links regional growth to immunization efforts against influenza, shingles and pneumococcal disease. - Better preventive-health awareness, broader access through pharmacies and healthcare providers, favorable reimbursement and vaccine-formulation advances are also cited as growth drivers in the U.S. and Canada. - By vaccine type, the market is split into monovalent and multivalent products. - Monovalent vaccines are projected to be the largest segment, at 56% of the market and about $35 billion in 2030. - The report says monovalent demand is supported by booster and catch-up vaccination programs, antigen-formulation research and manufacturing improvements. - Technology segments in the market include live attenuated, inactivated viral or bacterial, toxoid, recombinant and conjugate vaccines. - Main application areas include influenza, DPT, human papillomavirus, zoster, pneumococcal infections and hepatitis. - End users include healthcare companies and hospitals that distribute and administer vaccines. - Pfizer led global adult vaccine sales with a 30% share in 2025. - Other major companies listed include Merck & Co., Sanofi, GlaxoSmithKline, BioNTech, Moderna, CSL, Bavarian Nordic, Novavax, Takeda, Johnson & Johnson, AstraZeneca, Sinovac, Valneva, Emergent BioSolutions, Bharat Biotech, Serum Institute of India, Biological E, Hualan Biological Engineering, Shenzhen Kangtai Biological Products, Panacea Biotec and Inovio Pharmaceuticals. - The top 10 companies accounted for 100% of total revenue in 2025, according to the report. - Leading companies in the report’s share breakdown are Pfizer at 30%, Merck at 22%, Sanofi at 17%, GlaxoSmithKline at 13%, BioNTech at 6%, Moderna at 4%, CSL at 4%, Bavarian Nordic at 2%, Novavax at 2% and Takeda at 1%. - Raw material suppliers listed include Merck KGaA, Thermo Fisher Scientific, Lonza, Catalent, Sartorius, Avantor, Bio-Rad, Danaher, Corning, Cytiva, Eppendorf, MilliporeSigma, Fujifilm, Kaneka, Evonik, Wacker Chemie, BASF, DSM-Firmenich, Asahi Kasei, Sumitomo Chemical, Mitsubishi Chemical, Nitto Denko and Repligen. - Distribution players listed include McKesson, Cardinal Health, Cencora, AmerisourceBergen Healthcare, Owens & Minor, Medline, Henry Schein, Morris & Dickson, H. D. Smith Wholesale Drug Company, Anda, Smith Drug Company, Kinray, Dakota Drug, FFF Enterprises, Metro Medical Group, CuraScript Specialty Distribution, ASD Healthcare, BioCare SD, McKesson Plasma and Biologics, Rochester Drug Cooperative, Associated Pharmacies, Dakota Drug Cooperative, Value Drug Company, Dakota Drug Inc. Distribution and The Harvard Drug Group.

Between the lines: - The report points to a market concentrated among a small number of large vaccine makers because of strict regulatory, manufacturing and efficacy requirements. - Pfizer’s lead, along with the large shares held by Merck, Sanofi and GSK, suggests scale and distribution remain major barriers to entry. - mRNA is emerging as a key competitive theme, with faster development timelines and broader respiratory-disease coverage. - Moderna’s FDA approval of mRESVIA in May 2024 for adults 60 and older is one example of that shift. - The report’s growth estimates also reflect stronger government involvement, employer vaccination efforts and rising spending on healthy aging.

What's next: - The market is expected to keep expanding through 2030 as adult immunization coverage broadens and more countries add or strengthen vaccination programs. - Companies are likely to keep investing in next-generation vaccine platforms, improved delivery methods and manufacturing capacity. - Competitive positioning will depend on regulatory compliance, product innovation, partnerships and geographic expansion. - The report says both monovalent and multivalent segments could generate more than $23 billion in combined value by 2030.

The bottom line: - Adult vaccines are moving from a niche category to a core preventive-health market, with North America leading and a small group of pharmaceutical companies controlling most sales.